The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases

Abstract

Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), currently affect more than 6 million people in the United States. Unfortunately, there are no treatments that slow or prevent disease development and progression. Regardless of the underlying cause of the disorder, age is the strongest risk factor for developing these maladies, suggesting that changes that occur in the aging brain put it at increased risk for neurodegenerative disease development. Moreover, since there are a number of different changes that occur in the aging brain, it is unlikely that targeting a single change is going to be effective for disease treatment. Thus, compounds that have multiple biological activities that can impact the various age-associated changes in the brain that contribute to neurodegenerative disease development and progression are needed. The plant-derived flavonoids have a wide range of activities that could make them particularly effective for blocking the age-associated toxicity pathways associated with neurodegenerative diseases. In this review, the evidence for beneficial effects of multiple flavonoids in models of AD, PD, HD, and ALS is presented and common mechanisms of action are identified. Overall, the preclinical data strongly support further investigation of specific flavonoids for the treatment of neurodegenerative diseases.

References 119

1. 1.

   Przedborski S., Vila M., Jackson-Lewis V. Neurodegeneration: What is it and where are we? J. Clin. Investig. 2003;111:3-10.

   Not in our library10.1172/jci200317522

2. 2.

   Young J.J., Lavakumar M., Tampi D., Balachandran S., Tampi R.R. Frontotemporal dementia: Latest evidence and clinical implications. Ther. Adv. Psychopharmacol. 2018;8:33-48.

   Not in our library10.1177/2045125317739818

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   Prior M., Chiruta C., Currais A., Goldberg J., Ramsey J., Dargusch R., Maher P.A., Schubert D. Back to the future with phenotypic screening. ACS Chem. Neurosci. 2014;5:503-513.

   Not in our library10.1021/cn500051h

8. 8.

   Bishop N.A., Lu T., Yankner B.A. Neural mechanisms of ageing and cognitive decline. Nature. 2010;464:529-535.

   Not in our library10.1038/nature08983

9. 9.

   Schubert D., Maher P. An alternative approach to drug discovery for Alzheimer’s disease dementia. Future Med. Chem. 2012;4:1681-1688.

   Not in our library10.4155/fmc.12.109

10. 10.

    1Schubert D., Currais A., Goldberg J., Finley K., Petrascheck M., Maher P. Geroneuroprotectors: Effective geroprotectors for the brain. Trends Pharmacol. Sci. 2018;39:1004-1007.

    Not in our library10.1016/j.tips.2018.09.008

11. 11.

    Hao H., Zheng X., Wang G. Insights into drug discovery from natural medicines using reverse pharmacokinetics. Trends Pharmacol. Sci. 2014;35:168-177.

    Not in our library10.1016/j.tips.2014.02.001

12. 12.

    Swinney D.C. Phenotypic vs. target-based drug discovery for firrst-in-class medicines. Clin. Pharm. Therap. 2013;93:299-301.

    Not in our library10.1038/clpt.2012.236

13. 13.
    A Historical Overview of Natural Products in Drug Discovery · 2012

    No notice
14. 14.

    Yun B.-W., Yan Z., Amir R., Hong S., Jin Y.-W., Lee E.-K., Loake G.J. Plant natural products: History, limitations and the potential of cambial meristematic cells. Biotech. Gen. Eng. Rev. 2013;28:47-60.

    Not in our library10.5661/bger-28-47

15. 15.

    Bakoyiannis I., Daskalopoulou A., Pergialiotis V., Perrea D. Phytochemicals and cognitive health: Are flavonoids doing the trick? Biomed. Pharmacother. 2019;109:1488-1497.

    Not in our library10.1016/j.biopha.2018.10.086

16. 16.

    Beking K., Vieira A. Flavonoid intake and disability-adjuested life years due to Alzheimer’s and related dementias: A population-based study involving twenty-three developed countries. Public Health Nutr. 2010;13:1403-1409.

    Not in our library10.1017/s1368980009992990

17. 17.

    Commenges D., Scotet V., Renaud S., Jacqmin-Gadda H., Barberger-Gateau P., Dartigues J.F. Intake of flavonoids and risk of dementia. Eur. J. Epidemiol. 2000;16:357-363.

    Not in our library10.1023/a:1007614613771

18. 18.

    Gao X., Cassidy A., Schwarzschild M.A., Rimm E.B., Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson’s disease. Neurology. 2012;78:1138-1145.

    Not in our library10.1212/wnl.0b013e31824f7fc4

19. 19.

    Jones Q.R.D., Warford J., Rupasinghe H.P.V., Robertson G.S. Target-based selection of flavonoids for neurodegenerative disorders. Trends Pharmacol. Sci. 2012;33:602-610.

    Not in our library10.1016/j.tips.2012.08.002

20. 20.

    Duarte A.C.B., Santana M.G.S., Ofrfali G., Parisi de Oliveira C.T., Priolli D.G. Literature evidence and ARRIVE assessment on neuroprotective effects of flavonols in neurodegenerative diseases’ models. CNS Neurolog. Dis. Drug Targets. 2018;17:34-42.

    Not in our library10.2174/1871527317666171221110139

21. 21.
    Flavonoids as Therapeutic Agents in Alzheimer’s and Parkinson’s Diseases: A Systematic Review of Preclinical Evidences · 2018

    No notice
22. 22.
    Polyphenols in Parkinson’s Disease: A Systematic Review of In Vivo Studies · 2018

    No notice
23. 23.

    Ahmed R.M., Irish M., van Eersel J., Ittner A., Ke Y.D., Volkerling A., van der Hoven J., Tanaka K., Karl T., Kassiou M., et al. Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. Neurosc. Biobehav. Rev. 2017;74:126-138.

    Not in our library10.1016/j.neubiorev.2017.01.004

24. 24.

    Goedert M., Spillantini M.G. A century of Alzheimer’s disease. Science. 2006;314:777-781.

    Not in our library10.1126/science.1132814

25. 25.

    McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Humans Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939-944.

    Not in our library10.1212/wnl.34.7.939

26. 26.

    McKeith I., Cummings J.L. Behavioral changes and psychological symptoms in dementia disorders. Lancet Neurol. 2005;4:735-742.

    Not in our library10.1016/s1474-4422(05)70219-2

27. 27.

    Haas C. Strategies, development and pitfalls of therapeutic options for Alzheimer’s disease. J. Alzheimer’s Dis. 2012;28:241-281.

    Not in our library10.3233/jad-2011-110986

28. 28.
    Recent developments in Alzheimer's disease therapeutics · 2009

    No notice
29. 29.

    Gold M. Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough? Alzheimer’s Dement. 2017;3:402-409.

    Not in our library10.1016/j.trci.2017.04.005

30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

31. 31.

    Swerdlow R.H. Is aging part of Alzheimer’s disease, or is Alzheimer’s disease part of aging? Neurobiol. Aging. 2007;28:1465-1480.

    Not in our library10.1016/j.neurobiolaging.2006.06.021

32. 32.

    Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat. Neurosci. 2015;18:794-799.

    Not in our library10.1038/nn.4017

33. 33.

    Pallas M. Senescence-accelerated mice P8: A tool to study brain aging and Alzheimer’s disease in a mouse model. ISRN Cell Biol. 2012;2012:917167.

    Not in our library10.5402/2012/917167

34. 34.

    Morley J.E., Armbrecht H.J., Farr S.A., Kumar V.B. The senescence accelerated mouse (SAMP8) as a model for oxidative stress and Alzheimer’s disease. Biochim. Biophys. Acta. 2012;1822:650-656.

    Not in our library10.1016/j.bbadis.2011.11.015

35. 35.

    Cheng X.R., Zhou W.X., Zhang Y.X. The behavioral, pathological and therapeutic features of the senescence-accelerated mouse prone 8 strain as an Alzheimer’s disease animal model. Ageing Res. Rev. 2014;13:13-37.

    Not in our library10.1016/j.arr.2013.10.002

36. 36.

    Currais A., Goldberg J., Farrokhi C., Chang M., Prior M., Dargusch R., Daugherty D., Armando A., Quehenberger O., Maher P., et al. A comprehensive multiomics approach toward understanding the relationship between aging and dementia. Aging. 2015;7:937-955.

    Not in our library10.18632/aging.100838

37. 37.

    Stefanova N.A., Kozhevnikova O.S., Vitovtov A.O., Logvinov S.V., Rudnitskaya E.A., Korbolina E.E., Muraleva N.A., Kolosova N.G. Senescence-accelerated OXYS rats: A model of age-related cognitive decline with relevance to Alzheimer disease. Cell Cycle. 2014;13:898-909.

    Not in our library10.4161/cc.28255

38. 38.

    Devi L., Ohno M. 7,8 Dihydroxyflavone, a small molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2012;37:434-444.

    Not in our library10.1038/npp.2011.191

39. 39.

    Zhang Z., Liu X., Schroeder J.P., Chan C.-B., Song M., Yu S.P., Weinshenker D., Ye K. 7,8 Dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2014;39:638-650.

    Not in our library10.1038/npp.2013.243

40. 40.

    Zhou W.X., Li X., Huang D., Zhou W.X., Li T., Song W. No significant effect of 7,8 dihydroxyflavone on APP processing and Alzheimer-associated phenotypes. Curr. Alzheimer Res. 2015;12:47-52.

    Not in our library10.2174/1567205012666141218124243

Cited by papers we hold 1

• Neuroprotective Effects of Quercetin in Alzheimer’s Disease · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.